CDK-TCIP2

• Description:

  DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer[1].

• UNSPSC:

  12352005

• Target:

  BCL6; CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Immunology/Inflammation

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk-tcip2.html

• Purity:

  98.94

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C (OCC (NC) =O) =CC2=C (N1C) C (OC) =CC (NC3=NC (N4CCC (CC4) C (N5CCC6 (CCN (C (CN7CCC (CC7) C (NC8=NC=C (SCC9=NC=C (C (C) (C) C) O9) S8) =O) =O) CC6) CC5) =O) =NC=C3Cl) =C2

• Molecular Formula:

  C52H67ClN12O8S2

• Molecular Weight:

  1087.75

• References & Citations:

  [1]Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386 (6717) :eadl5361.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported